Chronic myelomonocytic leukaemia: A concise clinical and pathophysiological review

British Journal of Haematology

Volumn 165, Issue 3, 2014, Pages 273-286

  Patnaik, Mrinal M ^a   Parikh, Sameer A ^a   Hanson, Curtis A ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allogeneic stem cell transplant; ASXL1; Chronic myelomonocytic leukaemia; Hypomethylating agents; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIANEMIC AGENT; AZACITIDINE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RETINOIC ACID; RUBITECAN; SOTATERCEPT; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ASXL1 GENE; BCR ABL1 FUSION ONCOGENE; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; DIARRHEA; DISEASE FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; HEMOSIDEROSIS; HUMAN; IMMUNOPHENOTYPING; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON CHELATION; LEUKOCYTOSIS; LOCAL SKIN REACTION; LOW DRUG DOSE; MONOCYTOSIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; ONCOGENE; PATHOPHYSIOLOGY; PDGFRA GENE; PNEUMONIA; PRIORITY JOURNAL; REGULATOR GENE; RNA SPLICING; SPLICEOSOME; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; VOMITING;

ALLOGENEIC STEM CELL TRANSPLANT; ASXL1; CHRONIC MYELOMONOCYTIC LEUKAEMIA; HYPOMETHYLATING AGENTS; PROGNOSIS;

HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84898488422     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12756     Document Type: Article

References (67)

1. Abdel-Wahab, O., Pardanani, A., Patel, J., Wadleigh, M., Lasho, T., Heguy, A., Beran, M., Gilliland, D.G., Levine, R.L. & Tefferi, A. (2011) Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia, 25, 1200-1202.
2. Ades, L., Sekeres, M.A., Wolfromm, A., Teichman, M.L., Tiu, R.V., Itzykson, R., Maciejewski, J.P., Dreyfus, F., List, A.F., Fenaux, P. & Komrokji, R.S. (2013) Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leukemia Research, 37, 609-613.
3. Ahmed, F., Osman, N., Lucas, F., Neff, G., Smolarek, T., Bennett, J.M. & Komrokji, R.S. (2009) Therapy related CMML: a case report and review of the literature. International Journal of Hematology, 89, 699-703.
4. Apperley, J.F., Gardembas, M., Melo, J.V., Russell-Jones, R., Bain, B.J., Baxter, E.J., Chase, A., Chessells, J.M., Colombat, M., Dearden, C.E., Dimitrijevic, S., Mahon, F.X., Marin, D., Nikolova, Z., Olavarria, E., Silberman, S., Schultheis, B., Cross, N.C. & Goldman, J.M. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. The New England Journal of Medicine, 347, 481-487.
5. Aribi, A., Borthakur, G., Ravandi, F., Shan, J., Davisson, J., Cortes, J. & Kantarjian, H. (2007) Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer, 109, 713-717.
6. Bain, B.J. (2013) What is a promonocyte? American Journal of Hematology, 88, 919.
7. Beran, M. (2008) Chronic myelomonocytic leukemia. Cancer Treatment and Research, 142, 107-132.
8. Beran, M., Estey, E., O'Brien, S.M., Giles, F.J., Koller, C.A., Kornblau, S., Keating, M. & Kantarjian, H.M. (1998) Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia & Lymphoma, 31, 521-531.
9. Beran, M., Estey, E., O'Brien, S., Cortes, J., Koller, C.A., Giles, F.J., Kornblau, S., Andreeff, M., Vey, N., Pierce, S.R., Hayes, K., Wong, G.C., Keating, M. & Kantarjian, H. (1999) Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. Journal of Clinical Oncology, 17, 2819-2830.
10. Beran, M., Wen, S., Shen, Y., Onida, F., Jelinek, J., Cortes, J., Giles, F. & Kantarjian, H. (2007) Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leukemia & Lymphoma, 48, 1150-1160.
11. Braun, T., Itzykson, R., Renneville, A., de Renzis, B., Dreyfus, F., Laribi, K., Bouabdallah, K., Vey, N., Toma, A., Recher, C., Royer, B., Joly, B., Vekhoff, A., Lafon, I., Sanhes, L., Meurice, G., Orear, C., Preudhomme, C., Gardin, C., Ades, L., Fontenay, M., Fenaux, P., Droin, N. & Solary, E. (2011) Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood, 118, 3824-3831.
12. Cambier, N., Wattel, E., Menot, M.L., Guerci, A., Chomienne, C. & Fenaux, P. (1996) All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. Leukemia, 10, 1164-1167.
13. Cazzola, M., Della Porta, M.G. & Malcovati, L. (2013) The genetic basis of myelodysplasia and its clinical relevance. Blood, 122, 4021-4034.
14. Costa, R., Abdulhaq, H., Haq, B., Shadduck, R.K., Latsko, J., Zenati, M., Atem, F.D., Rossetti, J.M., Sahovic, E.A. & Lister, J. (2011) Activity of azacitidine in chronic myelomonocytic leukemia. Cancer, 117, 2690-2696.
15. Eissa, H., Gooley, T.A., Sorror, M.L., Nguyen, F., Scott, B.L., Doney, K., Loeb, K.R., Martin, P.J., Pagel, J.M., Radich, J.P., Sandmaier, B.M., Warren, E.H., Storb, R., Appelbaum, F.R. & Deeg, H.J. (2011) Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biology of Blood and Marrow Transplantation, 17, 908-915.
16. Elliott, M.A., Tefferi, A., Hogan, W.J., Letendre, L., Gastineau, D.A., Ansell, S.M., Dispenzieri, A., Gertz, M.A., Hayman, S.R., Inwards, D.J., Lacy, M.Q., Micallef, I.N., Porrata, L.F. & Litzow, M.R. (2006) Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplantation, 37, 1003-1008.
17. Feldman, E.J., Cortes, J., DeAngelo, D.J., Holyoake, T., Simonsson, B., O'Brien, S.G., Reiffers, J., Turner, A.R., Roboz, G.J., Lipton, J.H., Maloisel, F., Colombat, P., Martinelli, G., Nielsen, J.L., Petersdorf, S., Guilhot, F., Barker, J., Kirschmeier, P., Frank, E., Statkevich, P., Zhu, Y., Loechner, S. & List, A. (2008) On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia, 22, 1707-1711.
18. Fianchi, L., Criscuolo, M., Breccia, M., Maurillo, L., Salvi, F., Musto, P., Mansueto, G., Gaidano, G., Finelli, C., Aloe-Spiriti, A., Santini, V., Greco, M., Hohaus, S., Leone, G. & Voso, M.T. (2013) High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leukemia & Lymphoma, 54, 658-661.
19. Garcia-Manero, G., Gore, S.D., Cogle, C., Ward, R., Shi, T., Macbeth, K.J., Laille, E., Giordano, H., Sakoian, S., Jabbour, E., Kantarjian, H. & Skikne, B. (2011) Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Clinical Oncology, 29, 2521-2527.
20. Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., Olschwang, S., Xerri, L., Chaffanet, M., Mozziconacci, M.J., Vey, N. & Birnbaum, D. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 145, 788-800.
21. Gelsi-Boyer, V., Brecqueville, M., Devillier, R., Murati, A., Mozziconacci, M.J. & Birnbaum, D. (2012) Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. Journal of Hematology & Oncology, 5, 12.
22. Gerhartz, H.H., Marcus, R., Delmer, A., Zwierzina, H., Suciu, S., Dardenne, M., Solbu, G., de Witte, T., Jacobs, A. & Visani, G. (1994) A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC leukemia cooperative group. Leukemia, 8, 16-23.
23. Germing, U., Strupp, C., Aivado, M. & Gattermann, N. (2002) New prognostic parameters for chronic myelomonocytic leukemia. Blood, 100, 731-732. author reply 732-733.
24. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
25. Gunby, R.H., Cazzaniga, G., Tassi, E., Le Coutre, P., Pogliani, E., Specchia, G., Biondi, A. & Gambacorti-Passerini, C. (2003) Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematologica, 88, 408-415.
26. Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Ades, L., Fenaux, P., Beyne-Rauzy, O., Vey, N., Braun, T., Haferlach, T., Dreyfus, F., Cross, N.C., Preudhomme, C., Bernard, O.A., Fontenay, M., Vainchenker, W., Schnittger, S., Birnbaum, D., Droin, N. & Solary, E. (2013a) Prognostic score including gene mutations in chronic myelomonocytic leukemia. Journal of Clinical Oncology, 31, 2428-2436.
27. Itzykson, R., Kosmider, O., Renneville, A., Morabito, M., Preudhomme, C., Berthon, C., Ades, L., Fenaux, P., Platzbecker, U., Gagey, O., Rameau, P., Meurice, G., Orear, C., Delhommeau, F., Bernard, O.A., Fontenay, M., Vainchenker, W., Droin, N. & Solary, E. (2013b) Clonal architecture of chronic myelomonocytic leukemias. Blood, 121, 2186-2198.
28. Jankowska, A.M., Makishima, H., Tiu, R.V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C., O'Keefe, C., Hsi, E.D., List, A., Sekeres, M.A., Rao, A., McDevitt, M.A. & Maciejewski, J.P. (2011) Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood, 118, 3932-3941.
29. Kantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J.M., List, A., Fenaux, P., Sanz, G., Issa, J.P., Freireich, E.J. & Garcia-Manero, G. (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer, 113, 1351-1361.
30. Kar, S.A., Jankowska, A., Makishima, H., Visconte, V., Jerez, A., Sugimoto, Y., Muramatsu, H., Traina, F., Afable, M., Guinta, K., Tiu, R.V., Przychodzen, B., Sakaguchi, H., Kojima, S., Sekeres, M.A., List, A.F., McDevitt, M.A. & Maciejewski, J.P. (2013) Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica, 98, 107-113.
31. Kim, K.B., Faderl, S., Hwang, C.S. & Khuri, F.R. (2006) Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature. Journal of Clinical Pharmacy and Therapeutics, 31, 401-406.
32. Kohlmann, A., Grossmann, V., Klein, H.U., Schindela, S., Weiss, T., Kazak, B., Dicker, F., Schnittger, S., Dugas, M., Kern, W., Haferlach, C. & Haferlach, T. (2010) Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Journal of Clinical Oncology, 28, 3858-3865.
33. Krishnamurthy, P., Lim, Z.Y., Nagi, W., Kenyon, M., Mijovic, A., Ireland, R., Marsh, J., Ho, A.Y., Mufti, G.J. & Pagliuca, A. (2010) Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplantation, 45, 1502-1507.
34. Kroger, N., Zabelina, T., Guardiola, P., Runde, V., Sierra, J., Van Biezen, A., Niederwieser, D., Zander, A.R. & De Witte, T. (2002) Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic leukaemia working party of the European group for blood and marrow transplantation (EBMT). British Journal of Haematology, 118, 67-73.
35. Kuo, M.C., Liang, D.C., Huang, C.F., Shih, Y.S., Wu, J.H., Lin, T.L. & Shih, L.Y. (2009) RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia, 23, 1426-1431.
36. Laborde, R.R., Patnaik, M.M., Lasho, T.L., Finke, C.M., Hanson, C.A., Knudson, R.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2013) SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia, 27, 2100-2102.
37. Malcovati, L., Hellstrom-Lindberg, E., Bowen, D., Ades, L., Cermak, J., Del Canizo, C., Della Porta, M.G., Fenaux, P., Gattermann, N., Germing, U., Jansen, J.H., Mittelman, M., Mufti, G., Platzbecker, U., Sanz, G.F., Selleslag, D., Skov-Holm, M., Stauder, R., Symeonidis, A., van de Loosdrecht, A.A., de Witte, T. & Cazzola, M. (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 122, 2943-2964.
38. Mathew, R.A., Bennett, J.M., Liu, J.J., Komrokji, R.S., Lancet, J.E., Naghashpour, M., Messina, J.L., List, A.F., Moscinski, L.C. & Zhang, L. (2012) Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature. Leukemia Research, 36, 72-80.
39. Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S., Koeffler, H.P., Kern, W., Haferlach, C. & Schnittger, S. (2012) SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood, 120, 3080-3088.
40. Mittal, P., Saliba, R.M., Giralt, S.A., Shahjahan, M., Cohen, A.I., Karandish, S., Onida, F., Beran, M., Champlin, R.E. & de Lima, M. (2004) Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplantation, 33, 1005-1009.
41. Ocheni, S., Kroger, N., Zabelina, T., Zander, A.R. & Bacher, U. (2009) Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplantation, 43, 659-661.
42. Onida, F., Kantarjian, H.M., Smith, T.L., Ball, G., Keating, M.J., Estey, E.H., Glassman, A.B., Albitar, M., Kwari, M.I. & Beran, M. (2002) Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood, 99, 840-849.
43. Padron, E., Painter, J.S., Kunigal, S., Mailloux, A.W., McGraw, K., McDaniel, J.M., Kim, E., Bebbington, C., Baer, M., Yarranton, G., Lancet, J., Komrokji, R.S., Abdel-Wahab, O., List, A.F. & Epling-Burnette, P.K. (2013) GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood, 121, 5068-5077.
44. Pardanani, A., Ketterling, R.P., Li, C.Y., Patnaik, M.M., Wolanskyj, A.P., Elliott, M.A., Camoriano, J.K., Butterfield, J.H., Dewald, G.W. & Tefferi, A. (2006) FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leukemia Research, 30, 965-970.
45. Park, S., Labopin, M., Yakoub-Agha, I., Delaunay, J., Dhedin, N., Deconinck, E., Michallet, M., Robin, M., De Revel, T., Bernard, M., Vey, N., Lioure, B., Lapusan, S., Tabrizi, R., Bourhis, J.H., Huynh, A., Beguin, Y., Socie, G., Dreyfus, F., Fenaux, P. & Mohty, M. (2013) Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. European Journal of Haematology, 90, 355-364.
46. Patnaik, M.M., Lasho, T.L., Hodnefield, J.M., Knudson, R.A., Ketterling, R.P., Garcia-Manero, G., Steensma, D.P., Pardanani, A., Hanson, C.A. & Tefferi, A. (2012a) SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood, 119, 569-572.
47. Patnaik, M.M., Hanson, C.A., Sulai, N.H., Hodnefield, J.M., Knudson, R.A., Ketterling, R.P., Lasho, T.L. & Tefferi, A. (2012b) Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood, 119, 5674-5677.
48. Patnaik, M.M., Lasho, T.L., Finke, C.M., Hanson, C.A., Hodnefield, J.M., Knudson, R.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2013a) Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. American Journal of Hematology, 88, 201-206.
49. Patnaik, M.M., Padron, E., LaBorde, R.R., Lasho, T.L., Finke, C.M., Hanson, C.A., Hodnefield, J.M., Knudson, R.A., Ketterling, R.P., Al-kali, A., Pardanani, A., Ali, N.A., Komroji, R.S. & Tefferi, A. (2013b) Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia, 27, 1504-1510.
50. Patnaik, M.M., Itzykson, R., Lasho, T.L., Kosmider, O., Finke, C., Hanson, C.A., Knudson, R., Ketterling, R.P., Tefferi, A. & Solary, E. (2013c) ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: an international study of 431 patients. Blood (ASH Annual Meeting Abstracts), 122, 1510.
51. Quintas-Cardama, A., Kantarjian, H., O'Brien, S., Jabbour, E., Giles, F., Ravandi, F., Faderl, S., Pierce, S., Shan, J., Verstovsek, S. & Cortes, J. (2006) Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer, 107, 1525-1529.
52. Raje, N. & Vallet, S. (2010) Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Current Opinion in Molecular Therapeutics, 12, 586-597.
53. Ricci, C., Fermo, E., Corti, S., Molteni, M., Faricciotti, A., Cortelezzi, A., Lambertenghi Deliliers, G., Beran, M. & Onida, F. (2010) RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clinical Cancer Research, 16, 2246-2256.
54. Sorror, M.L., Storer, B. & Storb, R.F. (2009) Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biology of Blood and Marrow Transplantation, 15, 757-758.
55. Such, E., Cervera, J., Costa, D., Sole, F., Vallespi, T., Luno, E., Collado, R., Calasanz, M.J., Hernandez-Rivas, J.M., Cigudosa, J.C., Nomdedeu, B., Mallo, M., Carbonell, F., Bueno, J., Ardanaz, M.T., Ramos, F., Tormo, M., Sancho-Tello, R., del Canizo, C., Gomez, V., Marco, V., Xicoy, B., Bonanad, S., Pedro, C., Bernal, T. & Sanz, G.F. (2011) Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica, 96, 375-383.
56. Such, E., Germing, U., Malcovati, L., Cervera, J., Kuendgen, A., Della Porta, M.G., Nomdedeu, B., Arenillas, L., Luno, E., Xicoy, B., Amigo, M.L., Valcarcel, D., Nachtkamp, K., Ambaglio, I., Hildebrandt, B., Lorenzo, I., Cazzola, M. & Sanz, G. (2013) Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood, 121, 3005-3015.
57. Swerdlow, S., Camp, E., Harris, N.L., Jaffe, E.S., Stefano, P.A., Stein, H., Thiele, J. & Vardiman, J.W. (ed.) (2008) WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissue. International Agency for Research on Cancer (IARC), Lyon.
58. Symeonidis, A., van Biezen, A., Mufti, G., Finke, J., Beelen, D., Bornhauser, M., Greinix, H., Jouet, J.P., Volin, L., Schwerdtfeger, R., de Witte, T. & Kröger, N. (2010) Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome. Bone Marrow Transplantation, 45, S241, Abstract P803.
59. Takahashi, K., Pemmaraju, N., Strati, P., Nogueras-Gonzalez, G., Ning, J., Bueso-Ramos, C., Luthra, R., Pierce, S., Cortes, J., Kantarjian, H. & Garcia-Manero, G. (2013) Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood, 122, 2807-2811; quiz 2920.
60. Tefferi, A. & Gilliland, D.G. (2007) Oncogenes in myeloproliferative disorders. Cell Cycle, 6, 550-566.
61. Thorpe, M., Montalvao, A., Pierdomenico, F., Moita, F. & Almeida, A. (2012) Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leukemia Research, 36, 1071-1073.
62. Venditti, A., Tamburini, A., Buccisano, F., Scimo, M.T., Del Poeta, G., Maurillo, L., Cox, M.C., Abruzzese, E., Tribalto, M., Masi, M. & Amadori, S. (2000) A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. Annals of Hematology, 79, 138-142.
63. Wattel, E., Guerci, A., Hecquet, B., Economopoulos, T., Copplestone, A., Mahe, B., Couteaux, M.E., Resegotti, L., Voglova, V., Foussard, C., Pegourie, B., Michaux, J.L., Deconinck, E., Stoppa, A.M., Mufti, G., Oscier, D. & Fenaux, P. (1996) A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood, 88, 2480-2487.
64. Wijermans, P.W., Ruter, B., Baer, M.R., Slack, J.L., Saba, H.I. & Lubbert, M. (2008) Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leukemia Research, 32, 587-591.
65. Wong, E., Seymour, J.F., Kenealy, M., Westerman, D., Herbert, K. & Dickinson, M. (2013) Treatment of chronic myelomonocytic leukemia with azacitidine. Leukemia & Lymphoma, 54, 878-880.
66. Worsley, A., Oscier, D.G., Stevens, J., Darlow, S., Figes, A., Mufti, G.J. & Hamblin, T.J. (1988) Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. British Journal of Haematology, 68, 17-21.
67. Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H.P., Shih, L.Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S. & Ogawa, S. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 478, 64-69.